BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 10477007)

  • 1. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary morbidity with a modified peripheral loading technique of transperineal (125)i prostate implantation.
    Brown D; Colonias A; Miller R; Benoit R; Cohen J; Arshoun Y; Galloway M; Karlovits S; Wu A; Johnson M; Quinn A; Kalnicki S
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):353-60. PubMed ID: 10802359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method.
    Kang SK; Chou RH; Dodge RK; Clough RW; Kang HL; Bowen MG; Steffey BA; Das SK; Zhou SM; Whitehurst AW; Buckley NJ; Kim JH; Joyner RE; Sarmina I; Montana GS; Ingram SS; Anscher MS
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):937-45. PubMed ID: 11429221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Galbreath RW
    Urology; 2002 Oct; 60(4):650-5. PubMed ID: 12385927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy.
    Kollmeier MA; Stock RG; Cesaretti J; Stone NN
    J Urol; 2005 Mar; 173(3):808-12. PubMed ID: 15711274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
    Merrick GS; Butler WM; Dorsey AT; Lief JH
    Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. I-125 versus Pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective randomized multicenter trial.
    Wallner K; Merrick G; True L; Cavanagh W; Simpson C; Butler W
    Cancer J; 2002; 8(1):67-73. PubMed ID: 11895205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal resolution of urinary morbidity following prostate brachytherapy.
    Merrick GS; Butler WM; Lief JH; Dorsey AT
    Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):121-8. PubMed ID: 10758313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
    Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
    Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
    Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.
    Hinerman-Mulroy A; Merrick GS; Butler WM; Wallner KE; Allen Z; Adamovich E
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1367-82. PubMed ID: 15275722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.